Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Metabolism and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TPI1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TPI1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 and E. coli expression systems available. |
View TPI1 Products |
| Gene Delivery | TPI1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View TPI1 Products |
| Benchmark Ab | Anti-TPI1 Antibody Recombinant monoclonal antibody for positive control and target validation. |
View TPI1 Products |
| Validator | TPI1 siRNA Set For knockdown verification in functional cell-based assays. |
View TPI1 Products |
| Related Target A | GAPDH Downstream glycolytic enzyme; essential for coupled enzymatic activity assays with TPI1. |
View GAPDH Products |
| Related Target B | LDHA Key terminal glycolytic enzyme; synergistic target for disrupting the Warburg effect. |
View LDHA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-throughput screening of small molecule inhibitors | Highly stable recombinant TPI1 proteins with verified sequence identity and low endotoxin levels |
| Selectivity screening against other glycolytic isomerases | Homolog panel proteins strictly verified by mass spectrometry for off-target profiling |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live TPI1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TPI1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule inhibitors and combination metabolic therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting drug-resistant oncology profiles and autoimmune-related autoantigen pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Medical Centers, Biotech Startups | Solid Tumors, Drug-Resistant Gastric Cancer | Enzymatic Selectivity Assay (Need high-purity recombinant proteins) |
| Monoclonal Antibodies | Diagnostic and Immunology Developers | Autoimmune Diseases, Biomarker Assays | Antigen-Antibody Binding (Need sequence-verified mammalian-expressed TPI1) |
| RNA Therapeutics (siRNA) | Pre-clinical Research Consortia | Metabolic Reprogramming in Oncology | In vitro knockdown validation (Need sequence-specific siRNA sets) |